Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR

NCT05040724 is registered in ClinicalTrials.gov with Raincy Montfermeil Hospital Group as lead sponsor.

NCT NCT05040724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05040724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR
Lead sponsor
Raincy Montfermeil Hospital Group
Phase
Phase 3
Overall status
Unknown status
Start date
May 28, 2021
Completion date
June 30, 2022
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

to assess the reduction in the viral load of sars-cov-2 in patients receiving ivermectin compared to those receiving standard care